D&D Pharmatech Hosts NDR for Institutional Investors on Zabopegduptide MASH Phase 2 Biopsy Results

D&D Pharmatech will hold a non-deal roadshow (NDR) for domestic institutional investors on June 4, 2026, in Yeouido, Seoul.
The key discussion topic is the 48-week liver biopsy results from the US Phase 2 MASH trial of Zabopegduptide and a competitive analysis.
This IR event is sponsored by Hana Securities and is a routine corporate briefing without any capital raising or structural changes.
[AI Summary]D&D Pharmatech's sharing of Zabopegduptide's clinical data with institutional investors signals transparency in research progress, but the event itself is a routine IR activity with no direct impact on stock price or financial structure, thus assessed as neutral.